MedTrace Logo

E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy

NCT02879006 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-08-12

No results posted yet for this study

Summary

The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.

Conditions

Interventions

DRUG

Chinese Herbal Medication

Capsules, 26 month course, starting 2 months pre-OIT

DRUG

Placebo

Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT

DRUG

Omalizumab

4 months course, starting 2 months pre-OIT through the 2 month build-up phase

DRUG

Multi OIT

24 months of multi OIT (maintenance dose of 1gm each food allergen)

Sponsors & Collaborators

  • Xiu-Min Li

    lead OTHER

Principal Investigators

  • Julie Wang, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02879006 on ClinicalTrials.gov